The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus.
This study concerns the cloning, characterization, and expression of the lysin (LysK) from staphylococcal phage K in Lactococcus lactis. Lactococcal lysates containing recombinant LysK were found to inhibit a range of different species of staphylococci isolated from bovine and human infection sources, including methicillin-resistant Staphylococcus aureus. LysK thus has potential as an antimicrobial for applications in the prevention and/or treatment of infections caused by staphylococci.
O'Flaherty
S
S
Dairy Products Research Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland.
Coffey
A
A
Meaney
W
W
Fitzgerald
G F
GF
Ross
R P
RP
D000818:Animals; D000900:Anti-Bacterial Agents; D001433:Bacteriolysis / Q000235:genetics; D002417:Cattle; D004798:Enzymes / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D013294:Lactococcus lactis / Q000235:genetics; D016106:Methicillin Resistance; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013204:Staphylococcus Phages / Q000235:genetics*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000821:virology*
D000900:Anti-Bacterial Agents; D004798:Enzymes; D011994:Recombinant Proteins; C028806:lysin, streptococcus bacteriophage